| ¿µ¹® | complement | ÇÑ±Û | º¸Ã¼ |
|---|---|---|---|
| ¼³¸í | Ç×ü¿Í ¹ÝÀÀÇÏ¿© Ç×ü¿Í °áÇÕµÈ ¼¼Æ÷ÀÇ ÆÄ±«¸¦ ÀÏÀ¸Å°´Â ´Ü¹éÁúÀ» ¸»ÇÑ´Ù. Ç×ü°¡ Ç×ü¿Í °áÇÕÇÑ ¼¼Æ÷¸¦ ÆÄ±«ÇÏ´Â ¹æ¹ý¿¡´Â ¿©·¯ °¡Áö°¡ Àִµ¥ ±× ÁßÀÇ Çϳª·Î Ç×ü¿Í °áÇÕÇÑ ¼¼Æ÷ÀÇ Ç¥¸éÀ» ºÎºÐÀûÀ¸·Î ¼Õ»ó½ÃÄÑ ±× ¼¼Æ÷¸¦ ÆÄ±«ÇÏ´Â ¿ªÇÒÀ» ÇÏ´Â °ÍÀÌ ÀÌ º¸Ã¼ÀÌ´Ù. º¸Ã¼´Â 20°¡ÁöÀÇ ´Ü¹éÁú·Î ±¸¼ºµÇ¾î Àִµ¥ ¾àÀÚ·Î C·Î Ç¥½ÃÇÏ¸ç °¢ Á¾·ù¸¦ ³ªÅ¸³¾ °æ¿ì¿¡´Â C¿·¿¡ ¼ýÀÚ¸¦ ½á¼ Ç¥½ÃÇÑ´Ù. |
||
| ¿µ¹® | complement fixation reaction | ÇÑ±Û | º¸Ã¼°áÇÕ ¹ÝÀÀ, µµ¿òü°áÇÕ¹ÝÀÀ |
|---|---|---|---|
| ¼³¸í | Ç×ü¿ÍÀÇ ¹ÝÀÀ¿¡ ÀÖ¾î¼ º¸Ã¼¿Í °áÇÕÇÏ´Â Ç×ü¸¦ °Ë»çÇÏ´Â ¹æ¹ýÀ¸·Î, ÀÌ ¹ÝÀÀÀº ÃÖÃÊ¿¡ ±âÁöÇ׿ø, ÇǰËÇ÷û ¹× º¸Ã¼¸¦ È¥ÇÕÇÑ´Ù. Á¦2´Ü°è¿¡¼´Â ÀûÇ÷±¸¿Í À̰Ϳ¡ ´ëÀÀÇÏ´Â ¿ëÇ÷¼ÒÀÇ È¥ÇÕ¾×À» °¡ÇÑ´Ù. º» ¹ÝÀÀÈÄ ¿ëÇ÷ÀÌ ÀϾÁö ¾ÊÀ¸¸é º»Ã¼´Â Ç׿øÇ×ü°áÇÕ¹°¿¡ °áÇÕÇÑ °ÍÀÌ µÇ¾î ¾ç¼ºÀÌ µÇÁö¸¸, ¿ëÇ÷ÀÌ ÀÏ¾î³ °æ¿ì º¸Ã¼´Â °áÇÕÇÏÁö ¾Ê¾Æ ¼ÒºñµÇÁö ¾Ê±â ¶§¹®¿¡ À½¼ºÀÌ µÈ´Ù. º» ¹ÝÀÀÀº ±âÁöÇ÷ûÀ» ½á¼ Ç׿ø°ËÃâ¿¡ ÀÀ¿ëÇÒ ¼ö ÀÖÀ¸¸ç, ¸¶ÀÌÄÚÇö󽺸¶, ¸®ÄÉÃ, Ŭ¶ó¹Ìµð¾Æ, ¹ÙÀÌ·¯½º, ¸Åµ¶ µîÀÇ Áø´Ü¿¡ ¾²ÀδÙ. |
||
| ¿µ¹® | antiglobulin antibody | ÇÑ±Û | Çױ۷κҸ°Ç×ü |
|---|---|---|---|
| ¼³¸í | Ç×ü¿¡ ´ëÇÑ Ç×ü, Áï Æ¯Á¤ Ç×ü¿Í °áÇÕÇÒ ¼ö ÀÖ´Â Ç×ü. ´ë°³ Àΰ£ÀÇ Ç×ü¸¦ Áã¿¡ ÁÖ»çÇÏ¿© Áã·Î ÇÏ¿©±Ý Àΰ£ Ç×ü¿¡ ´ëÇÑ Ç×ü¸¦ ¸¸µé°Ô ÇÑ´Ù(Áã¿¡ À־ Àΰ£ÀÇ Ç×üµµ ¿ÜºÎ¿¡¼ µé¾î¿Â ¹°ÁúÀ̹ǷÎ). À̰ÍÀº ¿©·¯ °¡Áö ½ÇÇè¿¡¼ Àΰ£ÀÇ Æ¯Á¤Ç×ü¸¦ °ËÃâÇϴµ¥ ÀÌ¿ëÇÑ´Ù. |
||
| ¿µ¹® | antibody | ÇÑ±Û | Ç×ü |
|---|---|---|---|
| ¼³¸í | »ç¶÷ÀÇ ¸ö¿¡¼ ¸é¿ª¿¡ °ü°èÇÏ´Â ¹°Áú. ¿ÜºÎ¿¡¼ µé¾î¿Â ¹°Áú°ú ²À ¸Â°Ô °áÇÕÀ» ÇÏ¿©¼ ±× ¹°ÁúÀÇ »ý¹°ÇÐÀû Ȱµ¿À» ¾ïÁ¦Çϰųª ÆÄ±«Çϰųª »ç¶÷ÀÇ ´Ù¸¥ ¸é¿ª¼¼Æ÷·Î ÇÏ¿©±Ý °ø°ÝÇϱ⠿ëÀÌÇÏ°Ô ÇØÁÖ´Â ±â´ÉÀ» °¡Áö°í ÀÖ´Ù. Ç×ü´Â ¸é¿ª±Û·ÎºÎ¸°À̶ó´Â °ÍÀ¸·Î ÀÌ·ç¾îÁ® ÀÖ°í ±× ÇüÅ¿¡ µû¶ó IgA, IgE, IgG, IgDµîÀ¸·Î ³ª´«´Ù. |
||
| CF | 1) Cystic Fibrosis 2) Complement Fixing antibody 3) Conver... |
|---|---|
| CFA | colonization factor antigen; colony-forming assay; complement-fixing antibody; complete Freund's adj... |
| ICFA | incomplete Freund adjuvant; induced complement-fixing antigen |
| ACA | abnormal coronary artery; acrodermatitis chronica atrophicans; acute cerebellar ataxia; adenocarcino... |
| CRN | complement requiring neutralization |
| CF | Complement Fixing |
|---|---|
| CAMC | Complement-dependent antibody-mediated cytotoxicity |
| EAC | Erythrocyte antibody complement |
| N | Neutralization |
| PRN | Plaque Reduction Neutralization |
| complement-fixing antibody | Antibody that combines with and sensitises antigen leading to the activation of complement, which may result in cell lysis. Synonym: CF antibody, sensitizing substance. (05 Mar 2000) |
|---|---|
| fixing | 1. <orthopaedics> The act or operation of holding, suturing or fastening in a fixed position. The condition of being held in a fixed position. 2. <psychiatry> A term with two related but distinct meanings: 1. Arrest of development at a particular stage, which like regression (return to an earlier stage), if temporary is a normal reaction to setbacks and difficulties but if protracted or frequent is a cause of developmental failures and emotional problems. 3. <psychology> A close and suffocating attachment to another person, especially a childhood figure, such as one's mother or father. Both meanings are derived from psychoanalytic theory and refer to fixation of libidinal energy either in a specific erogenous zone, hence fixation at the oral, anal or phallic stage or in a specific object, hence mother or father fixation. 4. <technique> The use of a fixative to preserve histological or cytological specimens. 5. <chemistry> The process whereby a substance is removed from the gaseous or solution phase and localised, as in carbon dioxide fixation or nitrogen fixation. 6. <ophthalmology> The direction of the gaze so that the visual image of the object falls on the fovea centralis. 7. <chemistry> In film processing, the chemical removal of all undeveloped salts of the film emulsion, leaving only the developed silver to form a permanent image. 8. <zoology> A general term for determination of type, whether by designation, or indication. Origin: L. Fixatio (09 Jan 1998) |
| fixing eye | The eye, in cases of strabismus, that is directed toward the object of regard. (05 Mar 2000) |
| neutralization | 1. The act or process of neutralising, or the state of being neutralized. 2. <chemistry> The act or process by which an acid and a base are combined in such proportions that the resulting compound is neutral. See Neutral. Origin: Cf. F. Neutralisation. Source: Websters Dictionary (01 Mar 1998) |
| neutralization plate | A metal plate used for the internal fixation of a long bone fracture to neutralise the forces producing displacement. (05 Mar 2000) |
| neutralization test | A test to determine the antimicrobial activity of a serum by inoculating a susceptible animal with a mixture of the serum and the virus or other microbe being tested. Synonym: neutralization test. (05 Mar 2000) |
| neutralization tests | Titration of an antiserum by testing a series of dilutions of virus or immune serum to a given end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (cpe) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (id50) or die (ld50). (12 Dec 1998) |
| male chromosome complement | The large majority of males have a 46, xy chromosome complement (46 chromosomes including an x and a y chromosome). A minority of males have other chromosome constitutions such as 47,xxy (47 chromosomes including two x chromosomes and a y chromosome) and 47,xyy (47 chromosomes including an x and two y chromosomes). (12 Dec 1998) |
| genetic complement | <biology, genetics> The set of chromosomes contained within any one particular cell. (07 May 1998) |
| receptors, complement | Molecules on the surface of some B-lymphocytes and macrophages, that recognise and combine with the c3b, c3d, c1q, and c4b components of complement. (12 Dec 1998) |
| receptors, complement 3b | Molecular sites on or in some B-lymphocytes and macrophages that recognise and combine with complement 3b. The primary structure of these receptors reveal that they contain transmembrane and cytoplasmic domains, with their extracellular portion composed entirely of thirty short consensus repeats each having 60 to 70 amino acids. (12 Dec 1998) |
| receptors, complement 3d | Molecular sites on or in B-lymphocytes, follicular dendritic cells, lymphoid cells, and epithelial cells that recognise and combine with complement 3d. Human cr2 serves as a receptor for both c3dg and the gp350/220 glycoprotein of herpes virus 4, human, and binds the monoclonal antibody okb7, which blocks binding of both ligands to the receptor. (12 Dec 1998) |
| chromosome complement | The whole set of chromosomes for the species. In humans, the chromosome complement (which is also called the karyotype) consists of 46 chromosomes. (12 Dec 1998) |
| complement | <immunology> A term originally used to refer to the heat labile factor in serum that causes immune cytolysis, the lysis of antibody coated cells and now referring to the entire functionally related system comprising at least 20 distinct serum proteins that is the effector not only of immune cytolysis but also of other biologic functions. Complement activation occurs by two different sequences, the classic and alternative pathways. The proteins of the classic pathway are termed components of complement and are designated by the symbols C1 through C9. C1 is a calcium dependent complex of three distinct proteins C1q, C1r and C1s. The proteins of the alternative pathway (collectively referred to as the properdin system) and complement regulatory proteins are known by semisystematic or trivial names. Fragments resulting from proteolytic cleavage of complement proteins are designated with lower case letter suffixes, for example, C3a. Inactivated fragments may be designated with the suffix i, for example C3bi. Activated components or complexes with biological activity are designated by a bar over the symbol for example C1 or C4b, 2a. The classic pathway is activated by the binding of C1 to classic pathway activators, primarily antigen-antibody complexes containing IgM, IgG1, IgG3, C1q binds to a single IgM molecule or two adjacent IgG molecules. The alternative pathway can be activated by IgA immune complexes and also by nonimmunologic materials including bacterial endotoxins, microbial polysaccharides and cell walls. Activation of the classic pathway triggers an enzymatic cascade involving C1, C4, C2 and C3, activation of the alternative pathway triggers a cascade involving C3 and factors B, D and P. Both result in the cleavage of C5 and the formation of the membrane attack complex. Complement activation also results in the formation of many biologically active complement fragments that act as anaphylatoxins, opsonins or chemotactic factors. (05 Jan 1998) |
| complement 1 | The first complement component to act in the cytolysis reaction. It is a trimolecular complex held together with ca ions and when activated, has esterase activity which initiates the next step in the sequence. (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|